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1. Introduction
In-hospital and long-term outcomes after Coronary artery Bypass grafting (CABG) are im‐
pacted by various factors including age, gender and various co-morbidities including chron‐
ic obstructive pulmonary disease, hypertension, diabetes Mellitus, dyslipidemia, chronic
kidney disease (CKD), Peripheral arterial disease (PAD) and even connective tissue disor‐
ders such as systemic lupus erythematosus, and rheumatoid arthritis.
Both CKD and PAD have been considered a major risk factor for morbidity and mortality post-
CABG [1]. Therefore, both are always considered as a variable when calculating risk for peri-
operative mortality in patients undergoing CABG in the popular EUROSCORE and society of
Society of Thoracic Surgeons National Cardiac Surgery Database scoring system [1,2].
We will discuss the degree of importance of these co-morbidities along with the epidemiolo‐
gy, underlying proposed pathogenetic mechanisms, significant associated co-factors, and al‐
so highlight the pertinent existing data on these parameters.
2. CKD and its impact on outcomes after CABG
Chronic kidney disease is defined as derangement in renal function for a period of at least
six months. It is broadly divided into five stages based on creatinine clearance or glomerular
filtration rate (GFR) obtained from either Cockcroft-Gault or modification of diet in renal
disease (MDRD) equations [3,4]:
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Cockcroft-Gault equation: Creatinine Clearance (ml/min) = [([140 − age] × weight [kg])/72 ×
serum creatinine (mg/dl)] (× 0.85 for women),
MDRD equation: GFR (mL/min/1.73 m2) = 175 × (serum creatinine)-1.154 × (Age)-0.203 × (0.742 if
female) × (1.212 if African American) (conventional units)
Creatinine clearance or glomerular filtration rate (GFR) represents renal function. Declining
values represent a decline in renal function. Stage 1 refers to glomerular filtration rate (GFR)
>90 ml/min and is generally asymptomatic. GFR between 60-90 ml/min is stage 2 CKD.
Stage 3 is GFR between 30 and 60 ml/min and is further subdivided into Stage 3A (GFR
45-60 ml/min) and Stage 3B (GFR 30-45 ml/min). Stage 4 is defined by GFR between 15-30
ml/min while GFR <15 ml/min signifies Stage 5 and is considered an indication for renal re‐
placement therapy i.e. dialysis. The most common etiological factors for CKD include diabe‐
tes mellitus and hypertension resulting in diabetic nephropathy and hypertensive
nephrosclerosis, respectively.
The presence of CKD is considered a major independent predictor for development of coro‐
nary artery disease (CAD). An analysis from the atherosclerosis risk in communities (ARIC)
study, Manjunath et al demonstrated that in 15,350 subjects with a mean follow up of over 6
years, there was a significant increase in acute coronary syndrome events in patients with
stage 3 and 4 CKD (14.2%) compared with 5.5% in patients with stage 1 CKD (HR 1.38 (1.02,
1.87). Additionally, with every 10 ml/min/1.73 m2 decline in GFR, there was a progressive
increase in the incidence of cardiac events [5].
2.1. Proposed pathogenic mechanisms
Many factors contribute in the mechanisms associated in the renal contribution to increased
risk of cardiovascular events. We briefly discuss a few here: Impaired renal function is asso‐
ciated with reduced erythropoietin synthesis and consequent anemia, which has been asso‐
ciated with cardiovascular disease [6]. Reduced 1, 25 (OH) vitamin D synthesis is associated
with increased parathyroid hormone levels and higher prevalence of vascular calcification
and arteriosclerosis [7].
Abnormal calcium phosphate metabolism is a consequence of renal dysfunction and it has a
strong association with increased adverse cardiovascular events. Hyperphosphatemia and hy‐
percalcemia are distinctly independent risk factors leading to a greater occurrence of cardio‐
vascular events in patients with CKD and additionally, are also associated with poor surgical
outcomes in patients undergoing CABG. Increased calcium-phosphate product greater than 55
and hyperphosphatemia escalates the development of secondary hyperparathyroidism which
has been linked to increased osteoclastic activity and enhanced calcium-phosphate precipita‐
tion in the vasculature. There is also increase in the number of protein receptors in vessel cell
membrane which increases deposition of calcium. In patients with CKD, vitamin D deficiency
is also present even in the early stages. Vitamin D levels have a pivotal role in calcium-phos‐
phorus homeostasis, regulation of parathyroid hormone (PTH), and bone metabolism and
turnover. Three plausible mechanisms have been suggested in the protective effects of vitamin
D against cardiovascular disease mortality are that vitamin D can inhibit various foci of inflam‐
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mation which is a key pathogenic mechanism in atherosclerosis; vitamin D also has an anti-
proliferative effect on myocardial cell hypertrophy and proliferation and prevents remodeling
which underlies the pathogenesis of congestive heart failure and vitamin D acts as an inhibito‐
ry endocrine regulator for the renin-angiotensin system, which triggers the cascade of hyper‐
tension and decompensated heart  failure[8].  Thus,  with low 1,25 hydroxy cholecalciferol
levels, this effect is pronounced causing even further increase in cardiovascular risk.
We will discuss the outcomes of patients with CKD with the two modes of revascularization
namely percutaneous and then, surgical. Additionally, we will take into account the impact
of various comorbidities such as diabetes, dyslipidemias with respect to lipoprotein levels as
well as the role of oxidative stress in this patient population.
Although long-term mortality may improve with surgical revascularization in dialysis pa‐
tients with coronary artery disease, perioperative mortality continues to remain higher among
patients with end-stage renal disease (ESRD) requiring CABG. Various studies have compared
the outcomes of percutaneous coronary intervention (PCI) versus CABG and showed that mor‐
tality is not different [9-11]. However, these studies were from the 1990s and percutaneous
techniques have been refined since then with improved outcomes. Newer studies are required
to compare outcomes of percutaneous versus surgical revascularization.
2.2. Outcomes with percutaneous coronary intervention
In hemodialysis dependent patients (CKD stage 5), clinical outcomes of PCI are especially
poor. Before the advent of coronary stents 20 years ago, when percutaneous revasculariza‐
tion was performed with balloon angioplasty alone, it was found that patients with ESRD
experience a higher rate of coronary restenosis and recurrent angina, when compared to pa‐
tients without ESRD [12]. In another case control study of twenty patients with ESRD and 20
age and sex matched controls without renal disease, it was shown that the rate of restenosis
was 60% in ESRD patients, as compared to 35% in patients without renal disease. Restenosis
was found to be dependent on size of vessel dilated and there was increased prothrombotic
risk secondary to increased fibrinogen concentrations [13].
Many patients with ESRD experience silent ischemia. The possible mechanism being uremic
polyneuropathy and therefore, may not experience typical ischemic symptoms.
In a prospective study of 5327 patients undergoing percutaneous coronary intervention
(PCI) with a follow up of over five years, rate of death or myocardial infarction at one year
was 1.5% in CKD patients with creatinine clearance >70 ml/min, 3.6% in patients with creati‐
nine clearance between 50-70 ml/min, 7.8% between 30 and 49 ml/min and 18.1% with crea‐
tinine clearance less than 30ml/min. This study showed a progressive increase in adverse
outcomes with worsening renal function. CKD was a strong predictor of adverse cardiovas‐
cular events including death and MI [14].
2.3. CABG in patients with renal dysfunction
Even though conflicting studies exist, a large study has shown that although there is in‐
creased risk of mortality in patients with ESRD undergoing CABG when compared to pa‐
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tients without significant renal disease, it still portends a better outcome in terms of
mortality when compared to percutaneous revascularization in this patient population [15].
2.4. Hard endpoints after CABG
It has been shown that the lower the GFR, the worse the mortality after CABG. In a study of
2067 patients, it was found that estimated GFR was a powerful and independent predictor
of mortality in multivariate analysis. Estimated average GFR in patients who died was
57.9+/-17.6 mL/min per 1.73 m2 mg/dl, as compared to 64.7 +/- 13.8 mL/min per 1.73 m2 in
those who survived at an average follow-up for 2.3 years [16].
In a database review of 483,914 CABG patients over a three year period, it was shown that
the post-operative mortality rates for stage 2, stage 3, and stage 4 CKD patients were 1.8%,
4.3% and 9.3 % respectively. Also, there was a higher incidence of stroke, need for re-opera‐
tion, sternal infection, prolonged mechanical ventilation greater than 48 hours and a hospital
stay of longer than two weeks [17]. In a prospective study of 15,500 CABG patients over a
five year period, it was shown that dialysis dependent patients with CABG had higher risk
of in-hospital mortality as compared to non- dialysis dependent CABG patients (12.2% as
compared to 3.1%) and also significantly higher risk of mediastinitis (3.6 vs. 1.2%) [18].
One of the largest initial studies on CABG outcomes in ESRD patients 13 years ago was a
retrospective study on 82 patients in which patients had a mean follow-up of 3 years. 18.5 %
of the patients had left ventricular ejection fraction (LVEF) <0.45 and the aortic cross clamp
time was fairly good at 50 ± 3 minutes [10]. Mean number of grafts was 2.3. Sixty-two per‐
cent of patients received left internal mammary grafts. In this study, 30-day mortality rate
was 14.6%, and the mean survival rate at one, three and five years was 71%, 56% and 39%
respectively. Thirty day mortality was 14.6% due to a variety of causes including myocardial
infarction, cardiac arrest or cardiac tamponade. This study showed that although there was
high peri and post- operative as well as long term mortality in ESRD patients undergoing
CABG, there was a significant improvement in functional status as a result of CABG. The
use of internal mammary artery grafts was related with less in-hospital mortality as well.
Perioperative atrial fibrillation occurred in 12.1 % of patients within the first thirty days.
With patients having preoperative Newyork Heart Association (NYHA) class III or class IV
symptoms, LVEF less than 45% and age greater than 60 years, there was higher long term
mortality. The incidence of post- operative bleeding and sternal infection was 3.6% which
was higher when compared to patients not on dialysis.
Patients with CKD have a poor baroreceptor reflex. Therefore, they do not adjust very well
in conditions like post-operative hypotension. Therefore, poor cardiac output can be more
symptomatic in this group of patients [19].
In a study of 2438 CKD patients undergoing CABG over a three year period, operative mor‐
tality was 4.8% in individuals with stage 3 CKD and 7.1% in individuals with stage 4–5 CKD
while it was 2.2% in those without significant CKD [20]. CKD was associated with increased
post-operative blood transfusion requirement, acute kidney injury superimposed on CKD,
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myocardial injury and cardiac arrest. Use of blood transfusions and acute kidney injury
were strongly associated with in-hospital death in CKD patients.
2.5. Impact of mode of dialysis on outcomes after CABG
The mode of dialysis is equally important in influencing CABG outcomes, namely perito‐
neal (PD) and hemo-dialysis (HD). Peritoneal dialysis has been associated with worse out‐
comes when compared with hemodialysis [21,22]. Following CABG, diaphragmatic
splinting, atelectasis and hypoxemia can occur after early post-operative initiation of PD. In
a retrospective analysis of 105 patients, among whom 40 were on PD, and 65 on HD and all
patients had been on dialysis for at least 2 months prior to CABG, it was demonstrated that
the incidence of post- operative dialysate leak and peritonitis was 10% and 12.5% respective‐
ly in patients on PD. On the other hand, incidence of arterio-venous access thrombosis was
4.6% in patients on HD. Besides older age, PD was an independent risk factor of high opera‐
tive mortality (adjusted OR for in hospital mortality in PD patients was 22.58). Actual causes
of mortality included sepsis, cardiac arrest, pneumonia and gastrointestinal bleed. Chief in‐
fective organisms in septic patients were Staphylococcus aureus (coagulase negative), Pseu‐
domonas aeruginosa, and Enterococcus faecalis [21]. Risk of peritonitis is higher if
gastroepiploic artery is harvested for CABG as it requires diaphragmatic incision [22].
2.6. Impact of comorbidities in patients with CKD undergoing CABG
Diabetes and hypertension are the most common causes of CKD and they are also the major risk
factors for coronary artery disease, therefore, the incidence of CAD is higher in these patients.
2.6.1. Diabetes
Diabetes is present in almost one third of CKD patients undergoing CABG and is considered
a strong predictor of mortality in this patient group [23,24].
Szabo et al showed in a study of 2779 CABG patients that in 19.4% of patients with diabetes,
the cross-clamp and cardiopulmonary bypass times as well as the need for inotropic sup‐
port, transfusion of blood products and progression of renal failure were all higher in pa‐
tients with CKD. Additionally, the incidence of post-operative stroke was greater in diabetic
patients (4.3% vs. 1.7%). Five year survival rate was 84.4% in diabetic group while it was
91.3% in the non- diabetic group [25]. Another study showed that diabetes was an inde‐
pendent major predictor of morbidity and mortality in CABG patients. In 12,198 patients, it
was observed that the diabetic group had higher rates of post-operative mortality (3.9% vs.
1.6%) and stroke (2.9% vs. 1.4%). The five and ten year survival rates were 78% and 50%
among patients with diabetes as compared to 88 and 71% in the non-diabetic group [26].
Morris et al demonstrated in a study of 5654 patients undergoing CABG that the five year
survival rate for diabetic patients was 80% as compared to 91% for non- diabetics [27]. Out‐
comes of CABG are improved in diabetic patients who undergo grafting of internal mam‐
mary arteries, with two being better than one. In a retrospective analysis of 4382 patients
undergoing CABG, it was shown at 10 year follow-up that bilateral internal mammary ar‐
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tery grafting in addition to SVGs in diabetic patients improved survival and decreased need
for revascularization compared with single internal mammary artery grafting along with
SVGs [28]. The strong correlation between diabetes and cardiovascular outcomes including
survival and myocardial infarction is due to the diffusely extensive and rapidly progressive
nature of atherosclerotic coronary artery disease (CAD) in this group of patients. Various
other factors such as oxidized low-density lipoproteins (LDL), hyperglycemia causing ad‐
verse metabolic shifts, deranged fibrinolysis, increased coagulability, and advanced reno‐
vascular hypertension resulting in change in vessel architecture also contribute to the
progressive nature of CAD in diabetics. There is increased tendency for LDL induced athe‐
rosclerotic plaque formation and there is greater predisposition to thrombosis due to in‐
creased blood viscosity secondary to high plasma protein levels. There is also platelet and
endothelial dysfunction and increased production of thromboxane A2 and von- willebrand
factor along with decreased production of prostacyclins which creates a procoagulant state.
Coronary vasodilation is impaired as a result of loss of the hyperpolarizing mechanics nor‐
mally present in endothelial cells. Autonomic neuropathy in diabetes increases cardiac
chrontropic workload and subsequently leads to greater oxygen demand even at rest. There
is enhanced vascular tone in the coronary atherosclerotic plaque area leading to further re‐
duction in blood flow, producing orthostatic changes which leads to reduction in coronary
perfusion pressure and mitigates warning signs of ischemia such as angina [27,29-32].
2.6.2. Hypertension
Hypertension has also been associated with worse post CABG outcomes. In a multi centre
study of 2417 patients among whom patients were categorized into patients with normal
preoperative blood pressure, isolated systolic hypertension (systolic blood pressure >140
mm Hg), diastolic hypertension (diastolic blood pressure >90 mm Hg), or a combination of
systolic and diastolic hypertension. It was found that isolated systolic hypertension was as‐
sociated with a 40% greater risk of adverse outcomes such as stroke, renal failure, congestive
heart failure and all cause mortality after CABG. Even after correction for confounding risk
factor adjustment, the increased risk of adverse outcomes was significantly more pro‐
nounced in hypertensive patients [33].
2.6.3. Impact of other risk factors
In a study of 936 hemodialysis patients to elucidate correlation of recognized risk factors in
CKD patients, it was found that correlation with diabetes, smoking, African-American race
and increasing age of above fifty- five years was strong. It is suspected that non-traditional
risk factors like uremic environment and hemodialysis procedure using arteriovenous fistu‐
lae and high output state associated with these fistulae also impact the outcomes after
CABG adversely [34].
Dyslipidemia with a high LDL is a classic risk factor for development of CAD in the general
population. However, it is likely not a major risk factor in patients with advanced renal dis‐
ease. In a study of 210 dialysis dependent patients compared with 223 control subjects with
normal renal function, it was found that high density lipoprotein (HDL) levels were low
Artery Bypass442
while intermediate and very low density lipoprotein (IDL and VLDL) levels as well as tri‐
glyceride levels were higher in dialysis patients while there was no significant difference in
LDL levels [35]. In part, the role of decreased renal metabolism of lipids leads to a decreased
level of LDL is likely the cause.
Atherosclerosis is regarded as an inflammatory process [36]. It has also been shown that in
dialysis-dependent patients, oxidative stress is increased resulting in a pro-inflammatory en‐
vironment. As a result, incidence of cardiovascular events is increased. In a comparison
study of 28 healthy subjects and 31 patients with renal disease, it was discovered that gluta‐
thione peroxidase and superoxide dismutase activities were increased in patients on HD
while total glutathione and glutathione reductase activity is reduced resulting in increased
oxidative stress [37].
2.6.4. Impact of renal artery stenosis on CABG
Renal artery stenosis (RAS) can lead to refractory hypertension and gradual deterioration in
kidney function. The presence of underlying RAS and its effect on CABG outcomes has been
studied and variable results have been obtained. In a study of 798 patients undergoing iso‐
lated CABG with 18.7% having renal artery stenosis (>50% stenosis), acute renal failure de‐
veloped in 10.2% of patients post procedure. The mortality rate was 14% in patients who
developed acute renal failure (ARF) post operatively, while it was 0.2% in patients who did
not develop ARF. However, presence of RAS was not associated with development of ARF
post-operatively [38].
In a series of eighteen patients undergoing CABG who also had varying degrees of RAS
with mean serum creatinine of 2.6±2.7 mg/dl, RAS was not associated with adverse out‐
comes post-operatively [39].
2.7. Post-CABG complications in patients with CKD
Besides relatively increased short-term mortality in patients with CKD undergoing CABG,
they also encounter increased morbidity from infections, blood transfusions, and stroke. In a
retrospective analysis of 3954 patients where 82.7% patients had creatinine <1.5 mg/dl, and
16% had a serum creatinine level between 1.5 and 3.0 mg/dl, it was demonstrated that pa‐
tients with a serum creatinine level >1.5 mg/dl had a mortality of 7% compared to 3% in pa‐
tients with serum creatinine <1.5 mg/dl. Additionally, patients with a higher serum
creatinine level had a higher incidence of requiring prolonged mechanical ventilation (15%
vs. 8%), risk of stroke (7% vs. 2%), and bleeding complications (8% vs. 3%). Three infectious
complications (mediastinitis, graft harvest site infection, and chest wound infections) were
not different among these groups, whereas the occurrence of pneumonia and endocarditis
was significantly higher in patients with a higher serum creatinine [40].
2.7.1. Prolonged mechanical ventilation
It is believed that the prolonged mechanical ventilation and the need for re-intubation after
CABG in patients with renal dysfunction are due to a compromised ability to eliminate fluid
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volume, thereby predisposing patients to impaired alveolar gas exchange. Additionally, re‐
nal failure would result in decreased metabolism and elimination of sedative, anxiolytic and
analgesic drugs leading to impairment of respiratory drive.
A study showed that ventilatory complications such as need for greater than 48 hours of me‐
chanical ventilation and re- intubation is high in patients with significant renal dysfunction
undergoing CABG, when compared to patients with normal or mild renal dysfunction [40].
Another study showed a stepwise increase in need for prolonged mechanical ventilation as
the renal function deteriorates. In this study, the ventilator dependence rate greater than 24
hours was 8.6%, 14.7%, and 20.2%, as the stage of CKD increased [20].
2.7.2. Bleeding complications post CABG
Platelet dysfunction is a consequence of uremia in patients with CKD and they are more
prone to bleeding complications requiring blood transfusion. A study showed that signifi‐
cant renal dysfunction (serum creatinine of 1.5 to 3.0 mg/dl) significantly increases bleeding
complications such as disseminated intravascular coagulation, gastrointestinal hemorrhage,
or thoracic hemorrhage sufficient to require reoperation, or result in cardiac complications
such as cardiac arrest and low cardiac output [40].
The association of transfusion with mortality is particularly interesting. CKD impairs eryth‐
ropoiesis in the bone marrow due to reduced synthesis of erythropoietin, and is associated
with pre-operative anemia of chronic disease and also leads to increased risk of bleeding af‐
ter CABG [41]. Strategies to optimize preoperative hemoglobin and to minimize post-opera‐
tive transfusion could possibly improve operative outcomes in patients with CKD.
Transfusion needs are also increased as a result of uremia induced platelet dysfunction
which can cause an increase in bleeding tendency in these patients.
2.7.3. Other post-CABG complications in CKD
Interestingly, occurrence of post-operative atrial fibrillation has been shown to increase with
worsening renal function as well. In a study, the occurrence of atrial fibrillation was 22.2%.
19.2% and 16.5% in severe, moderate and mild CKD patients respectively [20].
Different studies have demonstrated the increased incidence of stroke in patients with CKD.
In an analysis on 2438 patients undergoing CABG, the incidence of stroke was 3%, 2.7% and
1.7% in severe, moderate and mild CKD groups [20].
Infectious complications occur more commonly in patients with CKD undergoing CABG as
well. A study showed that deep sternal infection, pneumonia, septicemia, infection involv‐
ing a leg vein and overall infection rate was higher as the CKD stage increased (9.0%, 5.1%,
and 3.5% in severe, moderate and mild CKD respectively) [20].
2.8. Impact of aortic cross clamp time in CABG
Aortic cross clamping time is the period during which an occlusive clamp is placed on the as‐
cending aorta close to the innominate artery as a part of achieving cardioplegia before proceed‐
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ing with coronary bypass grafting. The mechanism of induction of cardioplegia involves
prevention of repolarization of myocardial cell membrane due to the high potassium concentra‐
tion of the cardioplegic fluid causing inactivation of the sodium channels which initiate the ac‐
tion potential. The hypothermic fluid of cardioplegia induces asystole. When the solution is
administered in the aortic root it is termed antegrade and when administered in the coronary si‐
nus, it is called retrograde. Myocardial protection with cardioplegia decreases the energy de‐
mands of the heart by arrest of the contractile apparatus. This is considered to be an extension of
ischemia tolerance which is considered to minimize the deleterious effects of induced cardiac
arrest. However, it still is desirable to keep duration of cardioplegia at a minimum as the aortic
cross-clamp time is an important factor in predicting mortality in cardiac surgery and the lesser
it is, the better the outcomes. The metabolic processes resulting from cardiac ischemia include
sudden cessation of normal aerobic cardiac metabolic events, reduction in creatine phosphate,
initiation of anaerobic glycolysis, and build-up of lactate and alpha glycerol phosphate as well
as nucleotide metabolites. This is associated with contractile impairment and electrical path‐
way alterations consistent with typical EKG changes. The myocardial demand for high energy
phosphate substrates is increased when the availability of adenosine triphosphate decreases.
The predominant mode of energy derivation is switched to anaerobic glycolysis in the ischemic
tissue. With early ischemic component, contractile activity and later on ion transport utilizes
available adenosine triphosphate but gradually with the increase in ischemic time period, the
metabolic demands undergo a compensatory reduction to prevent further ischemic damage. Ir‐
reversible injury in cardiac muscle is highlighted by very low levels of adenosine triphosphate,
lack of energy production even by anaerobic mode, progressive accumulation of hydrogen
ions, adenosine monophosphate, and lactic acid with a consequently high osmotic load, mito‐
chondrial swelling and amorphous densities in matrix, and loss of integrity of the sarcolemmal
membrane. The precise mechanism of pathogenesis is still elusive. In animal models, severe is‐
chemia causes irreversible cell injury and death in one hour while with less severe ischemia in
the mid and sub-epicardial myocardium, survival is possible up to six hours. Irreversible injury
and cell death after six hours is inevitable. The ischemic injury changes reverse to a certain de‐
gree after reperfusion but how quickly and completely this transformation occurs is highly vari‐
able ranging from minutes to days.  Aerobic  metabolism is  restored early while  adenine
nucleotide pool and stunning resolve slowly [42].
Systolic dysfunction with reduction in LVEF <0.40 is also an indicator of poor prognosis in CKD
patients undergoing CABG. In a comparison study of aortic cross clamp times in patients with
normal versus reduced ejection fraction in 27,215 patients in which 99.8 % received antegrade,
retrograde or combined cardioplegia, it was found that prolonged aortic cross clamp time was
an independent predictor of mortality [43]. It was shown that a combination of reduced LVEF
and prolonged aortic cross clamp time especially with CKD compounds the ischemic effects
and increases overall risk of perioperative mortality. In this study, the mean aortic cross clamp
time was 68± 20 minutes, number of distal grafts was 3.1± 1.4 and 68.7% of patients underwent
grafting of the left internal mammary artery. The incidence of pulmonary complications was
12.2% and stroke was 2.27%. Fifty-two percent of the patients had baseline hypertension, 29%
had diabetes and 7% were dialysis dependent.
It has been shown that patients undergoing CABG with off pump or beating heart technique
experience improved post-operative outcomes and less perioperative mortality. In a study
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of 638 patients with acute coronary syndrome undergoing emergency CABG out of which
240 were operated off pump and 398 had standard on-pump CABG. 14.5% of patients were
in cardiogenic shock along with serum creatinine greater than 1.8 mg /dl. Follow-up was up
to 5 years. The results showed that in the off pump CABG group, in-hospital outcomes were
significantly better. With off-pump CABG, skin incision to culprit lesion revascularization
time was significantly reduced. There was less requirement for prolonged mechanical venti‐
lation, less need for inotropic support, less incidence of atrial fibrillation, lower stroke rate
(2.5 % vs. 6.7%), shorter intensive care unit stay and less sternal wound healing complica‐
tions (2.5% vs. 3.5%). The overall hospital mortality rate was also reduced (5.7%) as com‐
pared to those on cardiopulmonary bypass (8.6%) [44].
2.9. Conclusion
As we have discussed, numerous studies have shown that patients with CKD have worse
outcomes including an increased mortality and other complications after undergoing CABG,
when compared to patients without CKD. However, an increasing number of patients with
ESRD continue to undergo CABG and additionally, these patients are getting more complex
a higher presence of comorbidities including diabetes, hypertension and obesity [Figure 1].
However, fortunately, in-hospital mortality rates have declined remarkably from over 31%
to 5.4% in patients with ESRD (versus 4.7% to 1.8% among patients without ESRD) [45].
However, the mortality in ESRD patients remains 3-fold higher which indicates the need of
continued work to improve outcomes in these patients [Figure 2].
Figure 1. Graph depicting the increasing trend in the number of patients with end-stage renal disease (ESRD) under‐
going coronary artery bypass grafting (CABG) over a 15-year period (Data from Parikh DS, Swaminathan M, Archer LE,
et al. Perioperative outcomes among patients with end-stage renal disease following coronary artery bypass surgery in
the USA. Nephrol. Dial. Transpl 2010; 25(7):2275-2283).
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Figure 2. Graph depicting the constantly decreasing trend in mortality of patients with end-stage renal disease (ESRD)
undergoing coronary artery bypass grafting (CABG) compared to patients without ESRD, over a 15-year period (Data
from Parikh DS, Swaminathan M, Archer LE, et al. Perioperative outcomes among patients with end-stage renal dis‐
ease following coronary artery bypass surgery in the USA. Nephrol. Dial. Transpl 2010; 25(7):2275-2283)..
Studies have shown that cardiovascular risk modification using ACC/AHA guideline rec‐
ommended therapies for CAD, such as aspirin, beta blockers, hydroxymethyl coenzyme A
(HMG-Co A inhibitors popularly known as statins) and angiotensin converting enzyme
(ACE) inhibitors are used less frequently in patients with CKD when compared to patients
without CKD [14,46-48]. These medications have been shown to decrease the risk of cardio‐
vascular events across the population at risk. However, it is also true that many of those tri‐
als excluded patients with significant renal disease, which therefore poses a questions mark
on their efficacy in patients with advanced CKD. Randomized trials to evaluate efficacy of
these medications in patients with advanced renal dysfunction are warranted.
3. Peripheral arterial disease and CABG outcomes
The presence of peripheral arterial disease (PAD) plays a significant role in the potential
morbidity and mortality of patients undergoing CABG. Coexisting CAD and PAD signifi‐
cantly influences long term survival adversely [49,50]. In the Coronary Artery Surgery
Study (CASS), PAD was found to carry a higher risk of mortality even when compared to
patients who had previously experienced myocardial infarction and angina [51].PAD is in‐
cluded as a major risk factor when calculating risk of mortality in patients undergoing
CABG [1,2]. Non-invasive diagnostic testing for PAD includes segmental pressure measure‐
ment, treadmill stress, and Doppler ultrasound with the most significant information pro‐
vided by the ankle-brachial index (ABI). Normally it is greater than 1.0 while <0.9 is
considered abnormal. In patients with critical limb ischemia, the ABI is commonly <0.4. It is
suspected that in PAD patients, poor surgical outcomes after CABG could be related to rap‐
id progression of atherosclerotic coronary artery disease and more extensive small vessel
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CAD with poor target foci for intervention resulting in higher mortality rates. Also the high‐
ly variable rates of CAD progression in patients with and without PAD leads to poor out‐
comes as well [52].
In comparison with PCI, CABG has been shown to improve mortality significantly more in
patients with PAD. Data from 1305 consecutive patients undergoing coronary revasculariza‐
tion (PCI, n = 341; CABG, n = 964) between 1994 and 1996 showed that patients with PAD
undergoing CABG had better survival at 3 years when compared to PCI (hazard ratio 0.68;
95% CI 0.46-1.00; p = 0.05) [53].
In a retrospective analysis on 1,164 consecutive patients who underwent CABG (370 with
PAD), it was shown that PAD did not impact 30-day mortality. However, multivariable
analysis showed that patients with PAD had a significantly worse 9-year survival rate com‐
pared to patients without PAD (72.9% vs. 82.8%; adjusted hazard ratio, 1.7; p = 0.004) [54].
Trachiotis et al studied long-term survival in 11,830 CABG patients, 744 of whom had LVEF
<0.35. Among all patients, regardless of ventricular function, diabetes was linked with a 59%
increase in the relative risk of death [55]. It was shown by Birkmeyer et al that patients un‐
dergoing CABG with history of PAD had a 20% five-year mortality rate as compared to 8%
for those without known PAD [56,57]. Kaul et al showed that after risk factor adjustment,
patients with PAD had mortality rates twice as high as patients without PAD [58]. Loponen
et al showed in a multicenter study on 3000 patients that patients with PAD undergoing
CABG had a 71% greater in-hospital mortality rate than those without PAD [59].
In a ten year prospective study of 8000 patients with PAD undergoing CABG, it was seen
that they had a higher incidence of various intra- and post-operative complications includ‐
ing arrhythmias, stroke, pulmonary complications, low cardiac output state, longer hospital
stay, infections, and acute renal failure. These results have been borne out by other studies
as well [60-63].
The anatomic diversity of obstructive atherosclerotic disease process is particularly interest‐
ing. Patient can have isolated cerebrovascular disease involving carotid arteries, or lower ex‐
tremity arterial disease or a combination thereof. It has been shown that as the number of
involved arterial beds increases, the mortality increases. In a study on 2817 patients under‐
going CABG, it was demonstrated that when compared to patients with CAD alone, the
mortality was 1.6 times, 2.5 times, and 2.8 times higher for patients with concomitant cere‐
brovascular disease, lower extremity arterial disease and both cerebrovascular and lower ex‐
tremity arterial disease, respectively [64]. Another study found that in patients younger than
40 years, the most common pattern of lower extremity arterial disease is aortoiliac disease
while in patients older than 40 years, femoro-popliteal disease is predominant and causes
intermittent claudication in 65% of these patients [65].
Commonly, patients with iliac disease have hemodynamically significant stenoses, while
majority of patients with femoral disease have total occlusions characteristically involving
long segments of the superficial femoral artery. Consequently, percutaneous revasculariza‐
tion of the femoral arterial segments is technically difficult as compared to iliac endovascu‐
lar repair. The risk factors associated with PAD are similar to those for CAD, with diabetes
Artery Bypass448
and smoking being the major ones. Diabetes is a major predictor of outcomes of CABG in
patients with PAD. It is associated with more than 50% of major amputations in patients
with PAD. In a study of 261 patients by Jonason et al (47 diabetic and 224 non diabetic), at
six year follow up, showed an incidence of gangrene in 31% of diabetics as compared to 5%
in non-diabetics [66]. Also hypertension, strong family history of premature atherosclerotic
vascular disease, and hyperlipidemia are also contributory. Progression to severe ischemia
or amputation in symptomatic patients with intermittent claudication occurs at 1.4% per
year with poor prognosis in patients with diabetes and smoking [66,67].
The rate of all-cause mortality in patients with large-vessel PAD compared with the normal
population is three times greater, while the risk of cardiovascular mortality is six-fold more,
with the most common etiology being myocardial infarction or stroke [67]. In an analysis of
900 patients with LVEF of 0.35 or less, among whom 38% were diabetics, all-cause mortality
was 26% in diabetics and 24% in non-diabetics (p>0.05). However, 4 -year re-hospitalization
rates were 85% in diabetics and 69% in non-diabetics (p = 0.0001). The incidence of superfi‐
cial sternal wound infection was 3.3 times higher and of renal failure was 2.2 times greater
in diabetic patients as compared to non- diabetics [68].
Finally,  a  combination of  CKD and PAD is  even worse for  the overall  outcomes of  pa‐
tients  undergoing  CABG.  In  a  prospective  study  of  36,641  CABG  patients  over  a  ten
year  period,  long  term  survival  rates  of  patient  groups  stratified  as  non-  diabetic,  dia‐
betic  with PAD and CKD, and diabetics  without  PAD and CKD were determined.  The
follow  up  was  equivalent  to  154,140  person-years.  Annual  mortality  rates  for  non-dia‐
betic  and diabetic  groups were  3.1  deaths  per  100  person-years  and 4.4  deaths  per  100
person-years,  respectively.  The  annual  mortality  rate  for  diabetic  subjects  with  CKD,
PAD,  or  both  was  significantly  higher  at  9.4  deaths  per  100  person-years.  Thus,  pa‐
tients  undergoing  CABG  who  are  diabetic  along  with  having  PAD  and  CKD  are  at
highest  mortality  risk over long term follow up of  10 years  [69].
3.1. Impact of cerebrovascular disease on outcomes of CABG
Carotid artery stenosis  is  an important  risk  factor  in  determining post  CABG outcomes
such  as  stroke  and  additionally,  has  a  direct  impact  on  perioperative  mortality  [70,71].
Duplex  ultrasonography  or  contrast-based  techniques  can  be  utilized  pre-operatively  in
high risk patients  with age greater  than 65 years  and multiple  risk factors  such as  dia‐
betes  mellitus,  hypertension,  and  previous  transient  ischemic  attacks  or  stroke.  In  case
of  severe  carotid  disease,  surgical  planning might  need to  include carotid  endarterecto‐
my  along  with  CABG  simultaneously  versus  consideration  for  endovascular  repair  of
carotid disease pre-operatively.
In  a  study of  582  patients  undergoing  CABG,  preoperative  carotid  artery  duplex  scans
were  performed  to  assess  the  presence  of  asymptomatic  carotid  artery  stenosis.  >50%
uni-  or  bilateral  stenosis  was  present  in  22% while  >80% uni-  or  bilateral  stenosis  was
present  in  12% of  patients.  The  post-operative  hemispheric  stroke  rate  in  patients  with
carotid  stenosis  >50%  was  3.8%  as  compared  to  0.34%  in  patients  without  carotid
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stenosis  (p  =  0.0072).  Also  the  risk  of  hemispheric  stroke  was  5.3%  in  patients  with
unilateral  80% to  99% stenosis,  or  bilateral  50% to  99% stenosis,  or  unilateral  occlusion
with contralateral  50% or  greater  stenosis.  Patients  with  a  unilateral  50% to  79% steno‐
sis  did not  suffer  a  stroke in this  study [70].
In a study of 3344 patients undergoing CABG who were followed over a three year period
to assess the effect of carotid artery stenosis on perioperative stroke and mortality, it was
found that the clinical outcomes were directly related to the degree of carotid stenosis. Pa‐
tients with carotid stenosis <60% had a significantly less risk of suffering perioperative
stroke and mortality when compared to patients with >60% stenosis, especially patients with
a totally occluded carotid artery [71].
These  studies  signify  carotid  artery  disease  as  an  important  subset  of  patients  with
PAD  which  can  adversely  affect  post  CABG  outcomes  in  terms  of  incidence  of  stroke
and mortality  rates.
3.2. Impact of microvascular disease on CABG
Microvascular disease, such as that which occurs in diabetic patients has also been shown to
adversely affect outcomes after CABG. These complications generally stem from a cumula‐
tive poor glycemic control. In a study on 223 patients with diabetic retinopathy followed 11
years post-CABG, it was found that diabetic retinopathy was a strong independent predic‐
tor of overall mortality (relative risk [RR], 4.0), and repeat revascularization (RR, 3.0) [72].
3.3. Use of LIMA and SVG grafts
Use of internal mammary artery (IMA) grafts in patients undergoing CABG have been asso‐
ciated with improved short and long-term survival, increased patency and decreased perio‐
perative mortality. However, in patients with significant PAD, it could be the major source
of collateral flow to the lower extremities in patients with aorto-iliac disease. The finding
that the mammary artery collateralized the iliac artery led to major treatment changes in all
patients undergoing CABG [73]. Therefore, it is advisable to perform angiography of this
conduit before referral for CABG in patients with PAD.
In  a  study  on  21,873  patients  among  whom  87%  underwent  grafting  of  left  IMA,  and
were  followed  for  7  years,  there  was  a  significantly  decreased  risk  of  mortality  in  all
subgroups.  Additionally,  the  incidence  of  stroke,  repeat  intervention,  bleeding  compli‐
cations,  mediastinitis  or  sternal  dehiscence  requiring surgery  was  less  with  use  of  IMA
grafts.  The  adjusted  mortality  rate  was  2.2% vs.  4.9%,  and rate  of  stroke  was  1.6% vs.
1.9%  in  patients  undergoing  IMA  versus  no  IMA  grafting,  respectively.  Infective  me‐
diastinitis  or  sternal  dehiscence  was  seen  in  1.1% of  the  LIMA group and  1.3% of  the
non-LIMA group [74].
It  has  been  shown  that  use  of  LIMA  grafts  is  even  associated  with  lower  in  hospital
mortality  even  in  patients  with  a  higher  number  of  risk  factors  such  as  age  greater
than  70  years,  elevated  left  ventricular  end-diastolic  pressure,  left  ventricular  ejection
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fraction  less  than  40%,  small  body  mass  index,  or  clinical  presentation  in  acute  or
emergency  setting.  So,  there  is  a  proven  consistent  trend  of  protective  LIMA  effect  in
high risk groups as  well  [75].
3.4. Impact of PAD on graft failure in CABG
A  major  cause  of  short-term  mortality  post  CABG  and  therefore,  poor  surgical  out‐
come  is  graft  failure.  In  1972,  Lesperance  et  al  reported  that  out  of  a  total  of  105  sa‐
phenous  vein  grafts  (SVG)  used  during  CABG,  20%  had  early  occlusion  [76].  In  a
review  of  SVG  disease,  Motwani  and  Topol  showed  an  early  SVG  occlusion  rate  of
15%  and  elucidated  the  diverse  etiology  of  SVG  closure  [77].  At  one  month  post
CABG,  the  major  cause  of  graft  failure  is  thrombosis.  From  a  month  to  one  year  post
CABG,  intimal  hyperplasia  is  the  chief  contributor  while  after  one  year,  atherosclerotic
changes  have  been  primarily  implicated.  They  also  demonstrated  that  arterial  runoff
was  the  single  most  important  determinant  of  short-term graft  survival.  Occluded  ves‐
sels  distal  to  the SVG anastomosis  resulted in thrombosis  and graft  failures.
The  internal  diameter  of  the  mid-LAD  is  approximately1.7  mm,  while  that  of  the  sa‐
phenous vein is  4-5 mm. This difference leads to variable flow rates and slow flow ve‐
locity  in  the  SVG  as  compared  to  mid-LAD.  The  sluggish  flow  causes  red  blood  cell
sledging  and  consequent  thrombosis.  The  internal  diameter  of  the  IMA  is  almost
equivalent  the  mid-LAD, and thus  there  is  decreased risk  of  graft  thrombosis.  They al‐
so  highlighted that  LIMA graft  in  addition  to  matching favorable  dimensions  of  native
LAD,  lacks  valves,  has  less  endothelial  fenestrations,  and  has  a  greater  resistance  to
trauma  while  it  is  being  harvested  [78].  Other  advantageous  physiological  characteris‐
tics  of  the  IMA  include  higher  flow  reserve  and  shear  stress,  greater  nitric  oxide  and
prostacyclin  production  leading  to  vasodilation  and  inhibition  of  platelet  aggregation,
appropriate  relaxation  response  to  thrombin,  less  vasoconstrictor  sensitivity  and  high
vasodilator  sensitivity  along  with  decreased  number  of  fibroblast  growth  factor  recep‐
tors  thus reducing plaque formation [78].
In a patent population in whom both radial artery and SVG grafts were used for CABG, it
was found that radial artery grafts fared worse than SVGs in patients with PAD [79].
3.5. Off pump CABG and standard CABG
Off pump CABG (OPCAB) is referred to as CABG without use of cardiopulmonary bypass
or cardioplegia while on pump CABG is referred to the use of cardiopulmonary bypass and
cardioplegia. There have been various studies which generally show benefits of OPCAB as
compared to standard CABG. Benefits include less bleeding complications, stroke and renal
failure after OPCAB.
In a retrospective analysis of 68,000 patients by Ractz et al, 9000 OPCAB revascularizations
were performed with this group comprising many high-risk patients including those with
>60 years of age, female gender, low LVEF, previous history of CABG, stroke, PAD, conges‐
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tive heart failure, calcified aortic disease, and renal failure. It was seen that the standard
CABG group as compared to OPCAB group had higher rates of stroke (2.0% vs. 1.6%), high‐
er bleeding complications (2.2% vs. 1.6%), and prolonged hospital stay by one day. At 3-year
follow-up, the need for repeat revascularization was also greater in standard CABG versus
the OPCAB group [80].
In another retrospective study by Mack et al in which 17401 patients were reviewed and
7283 received OPCAB, it was found that even in patients with PAD among other risk fac‐
tors, patients undergoing OPCAB had improved mortality when compared to patients un‐
dergoing on-pump CABG (1.9% vs. 3.5%). The rate of complications including major
bleeding, wound infection, atrial fibrillation, permanent stroke, gastrointestinal and respira‐
tory complications, renal failure, myocardial infarction, and multiorgan failure was higher
in standard CABG group [81].
In another study comprising 214 patients at high risk (high EuroSCORE) with >50% of pa‐
tients with significant PAD, it was found that off-pump CABG was safer and was associated
with less early post-operative complications including multi-organ failure [82].
Patients with PAD are likely to have complex atheromatous plaques in the arch of aorta
which poses a risk for peri-operative stroke during manipulation for on-pump CABG sur‐
gery An analysis of 422 patients demonstrated that there was a significant reduction in post-
operative stroke in patients who had OPCAB when compared to patients undergoing on-
pump surgery (0.9% vs. 5.7%, p=0.007) [83]. Therefore, for patients with PAD needing
CABG, OPCAB would help avoid manipulation of aorta and in turn, decrease post-opera‐
tive cerebrovascular complications.
Over a period of time, an increasing body of evidence has indicated that OPCAB is better
than on-pump CABG, especially in high-risk groups. This includes a significant benefit of
OPCAB in patients with PAD as it reduces the risk of postoperative stroke. As it has been
shown in the SYNTAX trial, which is the largest contemporary trial comparing PCI versus
CABG, showed that the major risk with CABG appears to be the increased risk of stroke
from it [84]. OPCAB can, at least reduce that chance which might improve the overall bene‐
fit of CABG in patients with advanced CAD.
4. Conclusion
Based on current data, there is sufficient evidence to suggest that diabetes, peripheral arteri‐
al disease, CKD, on-pump CABG, increased aortic cross clamp and cardiopulmonary bypass
duration, lack of use of IMA graft are strongly associated with poor in hospital, short term
and long term outcomes after CABG. Rigorous modification of these risk factors to the maxi‐
mum possible extent preoperatively can result in further improvement of surgical outcomes
following CABG.
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